Clinimycin-T Uses

Did you have any side effects with this medicine?

What is Clinimycin-T?

Clinimycin-T belongs to the family of medicines called antibiotics.

Topical Clinimycin-T is used to help control acne. It may be used alone or with one or more other medicines that are used on the skin or taken by mouth for acne.

Topical Clinimycin-T may also be used for other problems as determined by your doctor.

Clinimycin-T is available only with your doctor's prescription.

Clinimycin-T indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.

Clinimycin-T Pediatric (Clinimycin-T palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.

Clinimycin-T is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting Clinimycin-T the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.

Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.

Pneumococci: Serious respiratory tract infections.

Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to Clinimycin-T.

In Vitro Susceptibility Testing

A standardized disk testing procedure2 is recommended for determining susceptibility of aerobic bacteria to Clinimycin-T. A description is contained in the Clinimycin-T® Susceptibility Disk (Clinimycin-T) insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the Clinimycin-T® Susceptibility Powder insert are followed, an MIC (minimal inhibitory concentration) of 1.6 mcg/mL may be considered susceptible; MICs of 1.6 to 4.8 mcg/mL may be considered intermediate and MICs greater than 4.8 mcg/mL may be considered resistant.

Clinimycin-T Susceptibility Disks 2 mcg. See package insert for use.

Clinimycin-T Susceptibility Powder 20 mg. See package insert for use.

For anaerobic bacteria the minimal inhibitory concentration (MIC) of Clinimycin-T can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clinimycin-T Pediatric and other antibacterial drugs, Clinimycin-T Pediatric should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

How should I use Clinimycin-T?

Use Clinimycin-T cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Clinimycin-T cream is for vaginal use only.
  • Wash your hands before and after using Clinimycin-T cream. To use, remove the cap from the tube. Screw the plastic applicator on the threaded end of the tube. Rolling the tube from the bottom, squeeze gently and force the medicine into the applicator. The applicator is filled when the plunger reaches its predetermined stopping point.
  • Unscrew the applicator from the tube and replace the cap. While lying on your back, firmly grasp the applicator barrel and insert into the vagina as far as it will possibly go without causing discomfort. Slowly push the plunger until it stops. Carefully remove the applicator from the vagina and throw the applicator away.
  • Use Clinimycin-T cream at bedtime. This will help keep the medicine in the vagina and reduce leaking.
  • Clinimycin-T cream works best if it is used at the same time each day.
  • To clear up your infection completely, use Clinimycin-T cream for the full course of treatment. Keep using it even if you feel better in a few days.
  • If you miss a dose of Clinimycin-T cream and you are using it regularly, use it as soon as possible. If several hours have passed or if it is nearing time for the next dose, do not double the dose to catch up, unless advised by your health care provider. Do not use 2 doses at once. If more than one dose is missed, contact your doctor or pharmacist.

Ask your health care provider any questions you may have about how to use Clinimycin-T cream.

Uses of Clinimycin-T in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Clinimycin-T is used to treat certain bacterial infections including infections of the lungs, skin, blood, female reproductive organs, and internal organs.

Clinimycin-T description

Clinimycin-T is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.

Clinimycin-T phosphate is a water soluble ester of Clinimycin-T and phosphoric acid.

Clinimycin-T phosphate is L-threo-α-D-galacto-Octopyranoside, methyl 7-chloro-6, 7, 8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.

The molecular formula is C18H34CIN2O8PS and the molecular weight is 504.96.

Clinimycin-T hydrochloride is the hydrated hydrochloride salt of Clinimycin-T. Clinimycin-T hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside monohydrochloride.

Clinimycin-T palmitate hydrochloride is a water soluble salt of ester of Clinimycin-T and palmitic acid. Clinimycin-T palmitate hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-palmitate monohydrochloride.

Clinimycin-T dosage


Clinimycin-T phosphate IM administration should be used undiluted.

Clinimycin-T phosphate IV administration should be diluted.

Adults: Clinimycin-T phosphate (IM or IV administration): The usual daily adult dosage of Clinimycin-T phosphate for infections of the intraabdominal area, female pelvis, and other complicated or serious infections is 2400-2700 mg given in 2, 3, or 4 equal doses. Less complicated infections due to more susceptible microorganisms may respond to lower doses such as 1200-1800 mg/day administered in 3 or 4 equal doses.

Doses of up to 4800 mg daily have been used successfully.

Single IM doses of greater than 600 mg are not recommended.

Clinimycin-T hydrochloride capsules (oral administration): 600-1800 mg/day divided in 2, 3 or 4 equal doses. To avoid the possibility of esophageal irritation, Clinimycin-T HCl capsules should be taken with a full glass of water.

Children (>1 month): Clinimycin-T phosphate (IM or IV administration): 20-40 mg/kg/day in 3 or 4 equal doses.

Clinimycin-T hydrochloride capsules or Clinimycin-T palmitate solution (oral administration): To avoid the possibility of esophageal irritation, Clinimycin-T HCl capsules should be taken with a full glass of water. Doses of 8-25 mg/kg/day in 3 or 4 equal doses. In children weighing ≤10 kg, ½ teaspoon (37.5 mg) of Clinimycin-T palmitate solution three times a day should be considered the minimum recommended dose.

Neonates (<1 month): Clinimycin-T phosphate (IM or IV administration): 15-20 mg/kg/day in 3 or 4 equal doses. The lower dosage may be adequate for small premature infants.

Elderly: Pharmacokinetic studies with Clinimycin-T have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration. Therefore, dosage adjustments are not necessary in the elderly with normal hepatic function and normal (age-adjusted) renal function.

Renal Impairment: Clinimycin-T dosage modification is not necessary in patients with renal insufficiency.

Hepatic Impairment: Clinimycin-T dosage modification is not necessary in patients with hepatic insufficiency.


Indications: Treatment of Beta-Hemolytic Streptococcal Infections: Refer to the dosage recommendations above under Dosage in Adults, Dosage in Children and Dosage in Neonates. Treatment should be continued for at least 10 days.

Inpatient Treatment of Pelvic Inflammatory Disease: Clinimycin-T phosphate 900 mg (IV) every 8 hrs daily plus an antibiotic with an appropriate gram negative aerobic spectrum administered IV, eg, gentamicin 2 mg/kg followed by 1.5 mg/kg every 8 hrs daily in patients with normal renal function. Continue (IV) drugs for at least 4 days and at least 48 hrs after the patient improves. Then continue oral Clinimycin-T hydrochloride 450-600 mg q6h daily to complete 10-14 days total therapy. Treatment of Chlamydia trachomatis Cervicitis: Clinimycin-T hydrochloride capsules orally 450-600 mg 4 times daily for 10-14 days.

Treatment of Toxoplasmic Encephalitis in Patients with AIDS: Clinimycin-T phosphate IV or Clinimycin-T hydrochloride orally 600-1200 mg every 6 hrs for 2 weeks followed by 300-600 mg orally every 6 hrs. The usual total duration of therapy is 8 to 10 weeks. The dose of pyrimethamine is 25 to 75 mg orally each day for 8 to 10 weeks. Folinic acid 10 to 20 mg/day should be given with higher doses of pyrimethamine.

Treatment of Pneumocystis carinii Pneumonia in Patients with AIDS: Clinimycin-T phosphate IV 600 to 900 mg every 6 hrs or 900 mg IV every 8 hrs or Clinimycin-T hydrochloride 300 to 450 mg orally every 6 hrs for 21 days and Primaquine 15 to 30 mg dose orally once daily for 21 days. Treatment of Acute Streptococcal Tonsillitis/Pharyngitis: Clinimycin-T hydrochloride capsules 300 mg orally twice daily for 10 days.

Treatment of Malaria: Clinimycin-T hydrochloride capsules or Clinimycin-T palmitate solution (oral administration).

Uncomplicated Malaria/P. falciparum: Adults: Quinine sulfate: 650 mg orally three times daily for 3 or 7 days plus Clinimycin-T: 20 mg base/kg/day orally divided three times daily for 7 days. Children: Quinine sulfate: 10 mg/kg orally three times daily for 3 or 7 days plus Clinimycin-T: 20 mg base/kg/day orally divided three times daily for 7 days.

Severe Malaria: Adults: Quinidine gluconate: 10 mg/kg loading dose IV over 1-2 hrs, then 0.02 mg/kg/min continuous infusion for at least 24 hrs (for alternative dosing regimen please refer to quinidine label). Once parasite density <1% and patient can take oral medication, complete treatment with oral quinine, dose as above, plus Clinimycin-T: 20 mg base/kg/day orally divided three times daily for 7 days. If patient not able to take oral medication, give 10 mg base/kg Clinimycin-T loading dose IV followed by 5 mg base/kg IV every 8 hrs. Avoid rapid IV administration. Switch to oral Clinimycin-T (oral dose as above) as soon as patient can take oral medication. Treatment course=7 days.

Children: Quinidine gluconate: Same mg/kg dosing and recommendations as for adults plus Clinimycin-T: 20 mg base/kg/day orally divided three times daily for 7 days. If patient not able to take oral medication, give 10 mg base/kg Clinimycin-T loading dose IV followed by 5 mg base/kg IV every 8 hrs. Avoid rapid IV administration. Switch to oral Clinimycin-T (oral dose as above) as soon as patient can take oral medication. Treatment course=7 days.

Prophylaxis of Endocarditis in Patients Sensitive to Penicillin: Clinimycin-T hydrochloride capsules or Clinimycin-T palmitate solution (oral administration).

Adults: 600 mg 1 hr before procedure; children: 20 mg/kg 1 hr before procedure. Alternatively, when parenteral administration is required: Clinimycin-T phosphate 600 mg IV 1 hr before procedure. Prophylaxis of Infection in Head and Neck Surgery: Clinimycin-T phosphate 900 mg diluted in 1000 mL normal saline for use as an intraoperative irrigant in contaminated head and neck surgery prior to wound closure.

Dilution and IV Infusion Rates: The concentration of Clinimycin-T in diluent for infusion should not exceed 18 mg/mL and infusion rates should not exceed 30 mg per minute. The usual infusion rates are as follows:.

Administration of >1200 mg in a single 1-hr infusion is not recommended.

Clinimycin-T interactions

See also:
What other drugs will affect Clinimycin-T?


With simultaneous use of Clinimycin-T with theophylline, aminophylline, caffeine, there is an increase in their concentration in blood plasma and thus increases the risk of toxic effects.

Erythromycin increases the concentrations of cyclosporine in the blood plasma and may increase the risk of nephrotoxicity.

Drugs that block tubular secretion prolongs T1/2 of erythromycin.

Incompatible with lincomycin, Clinimycin-T and chloramphenicol (antagonism).

Clinimycin-T reduces the bactericidal action of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems).

With simultaneous use of erythromycin increases the concentration of theophylline.

At the same time receiving chemotherapy, which is carried metabolism in the liver (carbamazepine, valproic acid, hexobarbital, phenytoin, alfentanil, dizopiramid, lovastatin, bromocriptine), may increase the concentration of these drugs in plasma (an inhibitor of microsomal liver enzymes).

IV injection of erythromycin increases the effects of ethanol (accelerating gastric emptying and decrease the duration of alcohol dehydrogenase in the gastric mucosa).

Erythromycin reduces the clearance of triazolam and midazolam and therefore may increase the pharmacological effects of benzodiazepines.

At the same time taking with terfenadine or astemizole may develop arrhythmias (fibrillation and ventricular flutter, ventricular tachycardia, until death); with dihydroergotamine or non hydrated ergot alkaloids may vasoconstriction to spasm, dysesthesia.

With simultaneous application Clinimycin-T slows elimination (increases the effect) of methylprednisolone, felodipine and anticoagulants of cumarine series.

In a joint appointment with lovastatin increased rhabdomyolysis.

Erythromycin increases the bioavailability of digoxin.

Erythromycin reduces the effectiveness of hormonal contraceptives.

Clinimycin-T side effects

See also:
What are the possible side effects of Clinimycin-T?

Clinical Study Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to Clinimycin-T (Clinimycin-T phosphate) in 368 patients. Clinimycin-T (Clinimycin-T phosphate) was studied in three clinical studies: placebo-controlled (n=85), active-controlled (n=263), and single-arm (n=20). The population was female, aged 18 to 78, who were diagnosed with bacterial vaginosis. Patient demographics in the trials were 51% Caucasian, 36% Black, 10% Hispanic, and 3% Asian, other or unknown. All patients received 100 mg Clinimycin-T phosphate cream intravaginally in a single dose.

Of the 368 women treated with a single dose of Clinimycin-T (Clinimycin-T phosphate), 1.6% of the patients discontinued therapy due to adverse reactions. Adverse reactions occurred in 126 of 368 patients (34%) treated with Clinimycin-T (Clinimycin-T phosphate) and in 32 of 85 patients (38%) treated with placebo.

Adverse reactions occurring in ≥ 1% of patients receiving Clinimycin-T (Clinimycin-T phosphate) in the three clinical studies are shown in Table 1.

Table 1: Adverse Reactions Occurring in ≥ 1% of Clinimycin-T (Clinimycin-T phosphate) -Treated Patients and at a Higher Rate than Placebo-Treated Patients

Adverse Event Clinimycin-T (Clinimycin-T phosphate)


n (%)



n (%)

Vaginosis fungal NOS* 52 (14) 7 (8)
Headache NOS 10 (3) 2 (2)
Back pain 6 (2) 1 (1)
Constipation 4 (1) 0 (0)
Urinary tract infection NOS 4 (1) 0 (0)
N = number of patients in intent-to-treat population

n (%) = number and percentage of patients with reported adverse reaction

NOS = not otherwise specified

* The use of Clinimycin-T may result in the overgrowth of non-susceptible fungal organisms in the vagina and may require antifungal treatment

Other reactions reported by < 1% of those women treated with Clinimycin-T (Clinimycin-T phosphate) include:

Dermatologic: Pruritic rash

Gastrointestinal: Diarrhea, vomiting

General: Fatigue

Immune System: Hypersensitivity

Nervous System: Dizziness

Reproductive System: Dysfunctional uterine bleeding, dysmennorrhea, intermenstrual bleeding, pelvic pain, vaginal burning, vaginal irritation, vulvar erythema<, vulvitis, vulvovaginal discomfort, vulvovaginal dryness, vulvovaginitis

Other Clinimycin-T Formulations

Clinimycin-T (Clinimycin-T phosphate) affords minimal peak serum levels and systemic exposure (AUCs) of Clinimycin-T compared to an oral or intravenous dose of Clinimycin-T. Data from well-controlled trials directly comparing Clinimycin-T administered orally to Clinimycin-T administered vaginally are not available.

The following additional adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of Clinimycin-T:

Gastrointestinal: Abdominal pain, esophagitis, nausea, Clostridium difficile-associated diarrhea

Hematopoietic: Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent Clinimycin-T therapy could be made in any of these reports.

Hypersensitivity Reactions: Maculopapular rash, vesiculobullous rash, and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Cases of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with Clinimycin-T. A few cases of anaphylactoid reactions have been reported.

Liver: Jaundice and abnormalities in liver function tests have been observed during Clinimycin-T therapy.

Musculoskeletal: Cases of polyarthritis have been reported.

Renal: Although no direct relationship of Clinimycin-T to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of Clinimycin-T (Clinimycin-T phosphate). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Dermatologic: Rash

Gastrointestinal: Hematochezia

Reproductive System: Vaginal erythema, vulvovaginal pruritis, vaginal discharge, vaginal swelling, vaginal bleeding, vaginal pain

Clinimycin-T contraindications

See also:
What is the most important information I should know about Clinimycin-T?

You should not use this medication if you are allergic to Clinimycin-T or lincomycin (Bactramycin, L-Mycin, Lincocin).

Do not take Clinimycin-T together with erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole, and others).

Before using Clinimycin-T, tell your doctor if you have kidney disease, liver disease, an intestinal disorder such as colitis or Crohn's disease, or a history of asthma, eczema, or allergic skin reaction.

Take this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Clinimycin-T will not treat a viral infection such as the common cold or flu.

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking Clinimycin-T and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

To be sure this medication is not causing harmful effects, your blood may need to be tested often. Your kidney or liver function may also need to be tested. Visit your doctor regularly.

If you need surgery, tell the surgeon ahead of time that you are using Clinimycin-T. You may need to stop using the medicine for a short time.

Active ingredient matches for Clinimycin-T:

Clindamycin in Lebanon.

List of Clinimycin-T substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Clinmas 150 mg x 30's (Lapi)$ 9.86
Clinmas 300 mg x 30's (Lapi)$ 16.74
Clinmax Skin 15 gm Gel (Palsons Drugs & Chemical Industries)$ 0.99
CLINMAX 1% W/W GEL 1 tube / 20 GM gel each (Palsons Drugs & Chemical Industries)$ 1.68
CLINMAX topical gel 1 % w/v x 20g (Palsons Drugs & Chemical Industries)$ 1.38
Clinmax 1% w/w Gel (Palsons Drugs & Chemical Industries)$ 1.68
Clinmide Clindamycin 1 % w/w, Nicotinamide 4 % w/w. GEL / 10g (Moraceae Pharmaceuticals (P) Ltd.)$ 1.11
10g (Moraceae Pharmaceuticals (P) Ltd.)$ 1.11
Clinmide Skin 10 gm Gel (Moraceae Pharmaceuticals (P) Ltd.)$ 1.03
CLINMIDE 1%/4% GEL 1 tube / 10 GM gel each (Moraceae Pharmaceuticals (P) Ltd.)$ 1.19
CLINMIDE topical gel 10g (Moraceae Pharmaceuticals (P) Ltd.)$ 1.11
Clinmide 1%/4% Gel (Moraceae Pharmaceuticals (P) Ltd.)$ 1.19
Clinof 1% w/w GEL / 20g (Intermed)$ 0.87
1 % w/w x 20g (Intermed)$ 0.87
Clinof Skin 20 gm Gel (Intermed)$ 0.87
CLINOF GEL 1 tube / 20 GM gel each (Intermed)$ 0.85
CLINOF topical gel 1 % w/w x 20g (Intermed)$ 1.03
Clinof NA Gel (Intermed)$ 0.85
Clinott -P 150 mg/1 mL x 2 mL (MacroPhar)
Clinott -P 150 mg/1 mL x 4 mL (MacroPhar)
Clinott 150 mg x 10 x 10's (MacroPhar)
Clinott 300 mg x 10 x 10's (MacroPhar)
Clinott cap 150 mg 10 x 10's (MacroPhar)
Clinott cap 300 mg 10 x 10's (MacroPhar)
Clinott-P inj 150 mg/mL 2 mL x 1's (MacroPhar)
Clinott-P inj 150 mg/mL 4 mL x 1's (MacroPhar)
Clinott-P inj 150 mg/mL 6 mL x 1's (MacroPhar)
Clinox 1% w/w T-GEL / 10g (Will Impex)$ 0.63
CLINOX topical gel 1 % w/w x 10g (Will Impex)$ 0.63
Clinox-N Clindamycin 1 % w/w, nicotinamide 4 % w/w. T-GEL / 15g (Will Impex)$ 1.19
CLINOX-N topical gel 15g (Will Impex)$ 1.19
Clinred 1% T-GEL / 20g (Encore)$ 1.41
CLINRED GEL 1 tube / 20 GM gel each (Encore)$ 1.41
CLINRED topical gel 1 % x 20g (Encore)$ 1.41
Clinred 1% w/w Gel (Encore)$ 1.54
Clinscar 1% w/w GEL / 10g (Intra Labs India Pvt Ltd)$ 0.71
1 % w/w x 10g (Intra Labs India Pvt Ltd)$ 0.71
Clinscar Skin 10 gm Gel (Intra Labs India Pvt Ltd)$ 0.71
CLINSCAR topical gel 1 % w/w x 15g (Intra Labs India Pvt Ltd)$ 0.95
CLINSCAR lotion 1 % w/v x 25ml (Intra Labs India Pvt Ltd)$ 1.19


  1. PubChem. "clindamycin". (accessed September 17, 2018).
  2. DrugBank. "clindamycin". (accessed September 17, 2018).
  3. MeSH. "Protein Synthesis Inhibitors". (accessed September 17, 2018).


The results of a survey conducted on for Clinimycin-T are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clinimycin-T. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet

Consumer reported price estimates

No survey data has been collected yet

Consumer reported time for results

No survey data has been collected yet

2 consumers reported age


Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 5 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 All Rights Reserved